Regent’s Park announces the award of a contract to provide Invasive Cardiology Services at Addenbrooke’s Hospital, Cambridge

[frame src=”https://www.rphc.co.uk/wp-content/uploads/2006/05/addensbrook.jpg” width=”300″ height=”187″ lightbox=”on” title=”Regent’s Park announces the award of a contract to provide Invasive Cardiology Services at Addenbrooke’s Hospital, Cambridge” align=”left” ]
Regent’s Park Heart Clinics Ltd. (Regent’s Park), an independent healthcare company specialising in the diagnosis and treatment of heart disease, today announced it has been awarded a long-term contract to provide invasive cardiology services at Addenbrooke’s Hospital in Cambridge. Addenbrooke’s Hospital is part of Cambridge University Hospitals NHS Foundation Trust. Addenbrooke’s is the teaching hospital for the University of Cambridge, a centre for specialist services, and a leader in research and development.

Dr. Ohri, Chief Executive of Regent’s Park said: “Winning this fiercely competitive tender is terrific news for our company. The success helps develop our nationwide distribution network of healthcare services and confirms our position as the UK’s leading managed cardiology services provider. The award also fits extremely well with our strategy to forge links with leading University Teaching Hospitals from across the NHS. Addenbrooke’s has a formidable reputation as a world-class centre of excellence in biomedical sciences and it will be a huge privilege for our staff and organisation to be working alongside this great institution.”

Dr. Ohri added: “We will be providing Cambridge with one of our highly-bespoke cardiac SuperLabsTM. The Cambridge SuperLabTM will be equipped with a brand new Siemens Artis dFC Cardiology System – This is state-of-the-art flat plate detector technology designed to improve the visualisation of detailed coronary anatomy. It will allow heart disease in our patients to be detected and managed more easily.”

Cambridge University Hospitals NHS Foundation Trust has an income of over £360 million and around 1100 beds, it employs over 6500 staff dedicated to the provision of a wide range of clinical and non-clinical services. The Trust is a leading international centre for biomedical research and medical education, and shares its site with the University of Cambridge, the Medical Research Council, the Wellcome Trust, the British Heart Foundation and Glaxo SmithKline. Addenbrooke’s is a national and regional centre for cancer services, liver transplants, organ transplantation, neurosciences and genetics.

Regent’s Park is an independent company dedicated to creating world-class centres for the diagnosis and treatment of heart disease. The company develops, owns and operates diagnostic and treatment facilities focusing exclusively on cardiovascular disease in partnership with leading hospitals and groups of cardiologists across the United Kingdom. Regent’s Park has been a national provider of cardiology services to the NHS since 2003, and has provided invasive cardiology procedures to over 8,500 patients through its facilities – coronary angiograms, coronary angioplasty, cardiac electrophysiology, defibrillator and pacing procedures. Regent’s Park prides itself on its ability to deliver high quality, cost effective cardiac care, through excellent service, efficient operations management, well trained staff, and uncompromising professionalism.

The Regent’s Park guiding philosophy is that every patient with heart disease should have access to healthcare of a world-class standard.